Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to assess the efficacy, antitumor activity, safety and tolerability of selinexor plus low-dose dexamethasone in participants with penta-refractory multiple myeloma or selinexor and bortezomib plus low-dose dexamethasone in participants with triple-class refractory multiple myeloma or selinexor and pomalidomide plus low-dose dexamethasone in participants with relapsed and/or refractory multiple myeloma.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT04414475
Study type Interventional
Source Karyopharm Therapeutics Inc
Contact Karyopharm Medical Information
Phone (888) 209-9326
Email clinicaltrials@karyopharm.com
Status Recruiting
Phase Phase 2
Start date July 1, 2020
Completion date June 30, 2025

See also
  Status Clinical Trial Phase
Not yet recruiting NCT06411301 - A Phase I Study to Assess the Tolerability of 225Ac-DOTATATE in Patients With Refractory and Relapsing Multiple Myeloma Expressing Somatostatin Receptors Phase 1
Recruiting NCT05008536 - Anti-BCMA CAR-NK Cell Therapy for the Relapsed or Refractory Multiple Myeloma Early Phase 1
Recruiting NCT06158412 - All-trans Retinoic Acid in Combination With a KPD Regimen for the Treatment of Refractory/Relapsed Multiple Myeloma Phase 2
Recruiting NCT05121103 - A Study of the Safety, Tolerability and Effectiveness of EZM0414 Investigative Product in Participants With Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B Cell Lymphoma Phase 1
Recruiting NCT04603872 - CAR-T Cells Combined With Dasatinib for Patients With Relapsed and/or Refractory B-cell Hematological Malignancies Early Phase 1
Recruiting NCT04657861 - APRIL CAR-T Cell Therapy for Patients With BCMA/TACI Positive Relapsed and/or Refractory Multiple Myeloma Early Phase 1
Terminated NCT05191472 - Pembrolizumab for the Treatment of Relapsed or Refractory Multiple Myeloma After Anti-BCMA CAR-T Therapies Phase 2
Active, not recruiting NCT04688853 - A Study to Investigate the Safety and Efficacy of TEG002 in Relapsed/Refractory Multiple Myeloma Patients Phase 1
Not yet recruiting NCT05050305 - Marizomib Central Nervous System (CNS) Phase 2
Recruiting NCT05546723 - LMY-920 for Treatment of Relapsed or Refractory Myeloma Phase 1
Not yet recruiting NCT06115135 - A Study of Venetoclax in Combination With Isatuximab and Dexamethasone for Relapsed/Refractory Multiple Myeloma Phase 2
Not yet recruiting NCT06225310 - A Trial of Selinexor, Ruxolitinib and Methylprednisolone Phase 1
Recruiting NCT05673083 - Impact of a Health Technology Intervention on Patient Activation in Multiple Myeloma
Completed NCT02176213 - Study of Pomalidomide, Cyclophosphamide, Dexamethasone in Relapsed/Refractory Multiple Myeloma Phase 2
Enrolling by invitation NCT04861480 - Dual-target CAR-T Cells (C-4-29) in the Treatment of Relapsed/Refractory Multiple Myeloma Phase 1
Completed NCT06012383 - Alvocade® (Bortezomib) Safety and Effectiveness Study
Not yet recruiting NCT05909826 - Carfilzomib, Oral Cyclophosphamide, and Dexamethasone for RRMM Phase 2
Completed NCT04811898 - A Dose Escalation Study of LNA-i-Mir-221 for Cancer Treatment Phase 1
Recruiting NCT05739188 - Safety and Efficacy of Anti-GPRC5D CAR-T Cells Therapy in the Treatment of r/r MM Phase 1/Phase 2
Recruiting NCT05747586 - BCMA CAR-NK For Patients With RRMM N/A